

OncoTherapy Science, Inc.

February 1, 2018

Announcement of research collaboration between OTS's subsidiary company and
Itabashi Medical System (IMS) group

OncoTherapy Science, Inc. (OTS) announces that one of our subsidiary companies, Cancer Precision Medicine, Inc. (CPM) has agreed on a research collaboration with IMS group (Meihokai Medical Corporation, Meirikai Medical Corporation, and Eil, Inc.) about liquid biopsy (*1) study for the early detection of post-operative tumor recurrence in gastric or colorectal cancer.

This collaborative research aims for the assessment of a possible clinical application of liquid biopsy which can detect circulating tumor DNA (ctDNA) released from remaining cancer cells or recurrent cancer cells after operation. This research will focus on the early detection of tumor recurrence in gastric or colorectal cancer patients of post-operation, through a collaboration with professor Yusuke Nakamura (the University of Chicago, previously director of Human Genome Center of Institute of Medical Science at the University of Tokyo) and below three medical institutions of the IMS group.

Meihokai Medical Corporation, Itabashi Chuo Medical Center

Meihokai Medical Corporation, Yokohama Asahi Chuo General Hospital

Meirikai Medical Corporation, Shin-Matsudo Chuo General Hospital

Based on the accumulated results and proof-of-concepts from the study, clinical application of liquid biopsy will be expanded to the IMS-affiliated medical institutions. Furthermore, CPM and IMS group will cooperate to improve the "Cancer Precision Medicine" according to personalized genetic information, for example throughout clinical sequencing approaches for cancer patients.

(*1) liquid biopsy

Cancer is a genetic disease with accumulation of genetic alterations. Recent advances in the next-generation DNA sequencing technologies have enabled to detect the presence of cancer in patient, by analyzing liquid specimens like blood and urine. This kind of approach is called as "liquid biopsy" which can detect mutated ctDNA with very high sensitivity. One of useful clinical applications of the liquid biopsy is very early detection of tumor recurrence, which may detect even earlier than tumor imaging examination like CT (Computed Tomography). Moreover, liquid biopsy is a non-invasive and safe method than collection of tumor tissue, and can be performed repeatedly.